Analytical Data
-
基因名
FLT3LG
- Application
-
别名
FLT3LG；Fms-related tyrosine kinase 3 ligand
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P49771
-
表达区间
27-181aa
-
氨基酸序列
TQDCSFQHSP ISSDFAVKIR ELSDYLLQDY PVTVASNLQD EELCGGLWRL VLAQRWMERL KTVAGSKMQG LLERVNTEIH FVTKCAFQPP PSCLRFVQTN ISRLLQETSE QLVALKPWIT RQNFSRCLEL QCQPDSSTLP PPWSPRPLEA TAPTA
-
分子量
17.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Recombinant Mouse CXCL15 Protein，His
Cat：PA1000-4667
Recombinant Human SPESP1 Protein，His
Cat：PA1000-4661
Protein Description
FLT3LG, or FMS-like tyrosine kinase 3 ligand, is a crucial cytokine that plays a significant role in the regulation of hematopoiesis and the development of dendritic cells. This protein acts primarily by binding to the FLT3 receptor, which is predominantly expressed on various hematopoietic progenitor cells. The FLT3LG-FLT3 interaction promotes the proliferation and differentiation of these progenitor cells into functional immune cells. Dysregulation of the FLT3 signaling pathway has been implicated in various hematological malignancies, including acute myeloid leukemia (AML) and certain lymphomas. Consequently, FLT3 has emerged as a promising therapeutic target, prompting extensive research into FLT3LG and its recombinant forms. Recombinant FLT3LG has potential applications not only in cancer therapy but also in immunotherapy and vaccine development, aiming to enhance immune responses through the promotion of dendritic cell maturation and function. Studies exploring the therapeutic efficacy of FLT3LG have demonstrated its ability to augment the immune system, making it a compelling candidate for combination therapies in treating malignancies with compromised immune response. As research progresses, understanding the precise mechanisms of FLT3LG in immune modulation will be critical in harnessing its potential for clinical applications.
